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ScienceDirectThe focus in cancer immunotherapy has mainly been on CD8 T
cells, as they can directly recognize cancer cells. CD4 T cells
have largely been neglected, because most cancers lack MHC
II expression and cannot directly be recognized by CD4 T cells.
Yet, tumor antigens can be captured and cross-presented by
MHC II-expressing tumor stromal cells. Recent data suggest
that CD4 T cells act as a swiss army knife against tumors. They
can kill cancer cells, if they express MHC II, induce tumoricidal
macrophages, induces cellular senescence of cancer cells,
destroy the tumor vasculature through cytokine release and
help CD8 T cells in the effector phase. We foresee a great future
for CD4 T cells in the clinic, grafted with tumor antigen
specificity by T cell receptor gene transfer, either alone or in
combination with engineered CD8 T cells.
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10, 13125 Berlin, Germany
Corresponding author: Blankenstein, Thomas (tblanke@mdc-berlin.de)
Current Opinion in Immunology 2021, 75:18–24
This review comes from a themed issue on Tumour immunology
Edited by Hans Stauss
https://doi.org/10.1016/j.coi.2021.09.005
0952-7915/ã 2021 The Authors. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
Introduction
Immunotherapy has entered the cancer treatment land-
scape successfully in the last decade. Checkpoint block-
ade and adoptive T cell therapy (ATT) have brought
great benefit to patients with high mutational burden
cancers or hematological malignancies, respectively. For
immunotherapy of solid cancers, responses are mainly
partial and of short duration. The focus in immunother-
apy has been mainly on CD8 T cells, because they can
directly kill cancer cells through recognition of peptide-
presenting MHC class I (pMHC I) on the cell surface. In
recent years, however, CD4 T cells and their role in anti-
tumor immunity have received more attention. CD4 T
cells are not a uniform cell population but exist as T
regulatory cells (Tregs) or conventional T helper cells of
different subtypes [1]. Hence, their role in cancer immu-
nity is controversial. Endogenous CD4 T cell responses
can augment immune tolerance in the tumorCurrent Opinion in Immunology 2022, 74:18–24 microenvironment and enhance tumor growth [2,3].
Naı̈ve tumor-specific T cells were shown to be tolerated
in the tumor draining lymph nodes to become Tregs and
reinforce tumor immune tolerance [4]. On the other hand,
adoptively transferred CD4 T cells have demonstrated
the ability to mount successful immune responses [5].
Here, we illuminate the potential of CD4 T cells to
enhance anti-tumor immune responses for more effective
and sustained responses in ATT.
Mechanisms of CD4 T cell involvement
While it has become clear that CD4 T cells are involved
in anti-tumor immunity, the exact mechanism how they
exert their effects is less clear. Most cancer cells do not
express MHC class II molecules (MHC II) and can thus
not be recognized by CD4 T cells directly but rather
through cross-presentation of tumor antigens by tumor
stromal cells. It can be assumed that cross-presentation of
tumor antigens on MHC II is more effective than MHC I,
as necrotic tumor cells or vesicles released by cancer cells
that are taken up by stromal cells primarily enter the
classical processing pathway for MHC II [6]. In most solid
tumors, monocytes/macrophages are the most abundant
MHC II-positive cells. Dependent on the presence or
absence of MHC II on the cancer cells and the CD4
subset involved, several different mechanisms of tumor
rejection have been suggested for CD4 T cells (Figure 1).
Cancer cell elimination by CD4 T cells
Only when cancer cells intrinsically express MHC II, they
can become direct targets for CD4 T cells via peptide-
MHC II (pMHC II) recognition. This is the case for most
hematological malignancies, for example, lymphomas. In
a model resembling Epstein-Barr Virus-associated lym-
phoproliferative disease, activation of latent membrane
protein 1 in B cells resulted in lymphomas that were
efficiently controlled by T cells. CD4 T cells eliminated
lymphomas in vivo in a cytotoxicity-independent, IFNg-
independent and TNFa-independent but likely MHC
II-dependent fashion [7]. In a melanoma transplantation
model, it was shown that tumor rejection by CD4 T cells
was dependent on IFNg and correlated with high gran-
zyme B expression in CD4 T cells [8]. Cancer cell-
intrinsic MHC II expression was found in several cancer
indications and correlated with favorable disease outcome
[9]. Still, the majority of cancers lack intrinsic MHC II
expression, even though it may be difficult to exclude low
level of expression.
DTH-like tumor rejection
In a mouse model of disseminated leukemia, adoptively
transferred CD4 T cells were necessary and sufficient towww.sciencedirect.com
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Mechanisms how CD4 T cells contribute to anti-tumor immunity.
(a) How CD4 T cells get activated. Tumor stromal cells, especially macrophages, internalize antigens from cancer cells via taking up necrotic
cancer cells or secreted antigen. Upon presentation of the contained antigens on MHC II on the macrophage, antigen-specific CD4 T cells get
activated by recognizing their target and in turn activate the macrophage, for example, through CD40/CD40L interaction. High cytokine levels can
occur by IFNg and TNFa secretion by CD4 T cells and macrophages. (b) Effector mechanisms by activated CD4 T cells. 1) Direct cytotoxicity by
CD4 T cells can occur when cancer cells themselves express MHC II on their surface. A cytotoxic phenotype involving granzymes and cytokines
renders CD4 T cells cytotoxic [7,8]. 2) Macrophages become effectors when activated by CD4 T cells and destroy tumor cells by upregulating
nitric oxide synthetase (iNOS) and producing NO [11,12]. 3) Growth arrest of cancer cells can be achieved by inducing senescence through IFNg
and TNFa produced by CD4 T cells [14]. 4) IFNg and TNFa produced by CD4 T cells and macrophages synergize to destruct blood vessels in an
early phase of tumor rejection [23].reject the tumor cells proposedly by a reaction similar to
delayed type hypersensitivity (DTH) involving activa-
tion of tumoricidal macrophages [10]. Similarly, in a
mouse model of MHC II-negative plasmacytoma it was
shown that bone marrow-resident macrophages became
effectors to kill tumor cells when activated by CD4 T
cells through IFNg [11]. As mechanism, it was proposedwww.sciencedirect.com that upon activation of macrophages, they upregulated
inducible nitric oxide synthetase (iNOS) and the thereby
produced NO eventually destroyed the tumor cells [12].
The tumor-specific antigen (an immunoglobulin V
region-derived idiotypic peptide) was secreted by the
cancer cells, which was proposed a prerequisite for the
described mechanism. In a B cell lymphoma model,Current Opinion in Immunology 2022, 74:18–24
20 Tumour immunologywhere the tumor antigen (idiotypic lambda light chain)
was either secreted or expressed as truncated intracellular
version, lymphoma rejection in TCR-transgenic mice
occurred only when the antigen was secreted [13]. Nev-
ertheless, tumor-resident macrophages showed similar
tumor-specific activation for both variants, thus showing
that cross-presentation of intracellular antigen occurred
efficiently in the antigen-retaining variant [12]. This is
promising for adoptive transfer of effector CD4 T cells as
many tumor antigens are not secreted. Together these
data show an effector function for tumor-resident macro-
phages in anti-tumor immunity mediated by CD4 T cells.
CD4 T cells induce senescence in cancer cells
Activated CD4 T cells often secrete simultaneously
IFNg and TNFa, typical for Th1 cells. It was shown
that IFNg and TNFa produced by adoptively transferred
CD4 T cells caused cytokine-induced senescence result-
ing in growth arrest of cancer cells [14]. Inhibition of
tumor growth depended on the senescence-inducing cell
cycle regulators p16Ink4a/p19Arf (Cdkn2a) or p21Cip1
(Cdkn1a) in the cancer cells. Human melanoma metasta-
ses that progressed after immune checkpoint blockade
therapy were defective of senescence-inducing genes
[15]. In this mechanism, cancer cells are the direct targets
of IFNg and TNFa, but recognition of pMHC II is
mediated by stromal cells requiring cross-presentation
of cognate tumor antigens. Whether such a cancer cell
intrinsic mechanism allows rapid immune escape,
remains to be seen.
The first event during tumor rejection: IFNg and TNFa
destroy the tumor vasculature
IFNg has multiple biological activities. Its role during
tumor rejection has mainly been associated with upregu-
lation of MHC I, resulting in more efficient cancer cell
recognition. There is ample evidence for this assumption
and in this regard, it is interesting that IFNg produced by
T cells diffuses widely into the tumor microenvironment
and alters cell signaling in remote tumor cells [16,17].
The necessity of IFNg to act on the cancer cells is
illustrated by the observation that IFNg-unresponsive-
ness has been implicated in escape from CD8 T cell
attack in mouse models and humans [18,19]. Yet, experi-
ments some time ago had shown that IFNg needed to act
on non-bone marrow-derived cells to inhibit blood vessel
formation in the tumor [20,21]. This was the case in
models of both, CD4 and CD8 T cell mediated tumor
cell rejection, also when the cancer cells were IFNg
receptor (IFNg-R)-deficient [21,22]. In a model of large
vascularized tumors in mice with selective IFNg-R
expression in individual cell types/organs, it was shown
that endothelial cells were a necessary and sufficient
target of IFNg to initiate tumor regression [23]. In this
set of experiments, IFNg was locally induced in the solid
tumors. Ischemia-like blood vessel regression preceded
cancer cell death, compatible with findings showing thatCurrent Opinion in Immunology 2022, 74:18–24 perforin-deficient but not IFNg-deficient T cells eradi-
cated large established tumors, raising doubts about a
series-killing mechanism [24]. Furthermore, IFNg and
TNFa synergized in vessel destruction. Using intravital
microscopy, it was shown that the mechanism for IFNg
involves controlled blood vessel regression resembling
physiological remodeling, while TNFa caused bursting
of the blood vessels, both leading to collapse of the tumor
as secondary event [23]. In conclusion, IFNg and
TNFa are both produced by effector CD4 T cells and
cause blood vessel and hence tumor destruction.
It should be noted that the effector molecules required for
solid tumor destruction are largely overlapping for CD4
and CD8 T cells: both produce IFNg and TNFa upon
antigen recognition, when appropriately activated. If
CD4 T cells reject solid tumors by cutting the blood
supply, which then leads to collapse of the entire tumor
tissue (except perhaps of the rim of the tumor) without
directly recognizing the cancer cells, the cancer cells
should undergo apoptosis independent of whether they
express the target antigen or not. This phenomenon,
termed bystander elimination of antigen-negative var-
iants, was first shown for CD8 T cells recognizing over-
expressed model antigens cross-presented through MHC
I on tumor stromal cells, resulting in increased effector
function [25]. Assuming more efficient cross-presentation
through MHC II compared to MHC I, one might expect
more pronounced bystander elimination of CD4 T cells
compared to CD8 T cells. An advantage of CD4 T cells
over CD8 T cells is also that they will not select tumor
antigen-negative or MHC I-negative variants and remain
active as long as there is sufficient antigen expressed by
the cancer cells to feed MHC II-positive stromal cells.
One should not expect, however, that the last cancer cell
is eradicated by CD4 T cells alone.
Cooperation of CD4 and CD8 T cells in the
effector phase
While it has been appreciated that CD4 T cells are
essential to mediate a fully integrated immune response,
focus has been primarily on helper functions during the
priming phase [26]. By recognizing their antigen on the
same dendritic cell, CD4 T cells enhance priming of
specific CD8 T cells through activation of dendritic cells
by CD40/CD40L interaction and thereby stimulate an
effective immune response [26]. In addition to help in the
priming phase, which is primarily relevant for endoge-
nous CD8 T cell responses, there is evidence that the
combined action of CD4 and CD8 T cells locally at the
tumor side leads to enhanced anti-tumor immunity
[27,28,29,30] (Figure 2). In a model of transplanted
fibrosarcoma, bystander killing of antigen-negative cancer
cell variants through stromal targeting was observed only
when antigen targets for both CD4 and CD8 T cells were
expressed by the same cancer cells and not when cancer
cells expressing only one antigen target were mixed [27].www.sciencedirect.com
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CD4 and CD8 T cell cooperation in the effector phase.
CD4 effector T cells (CD4 TE) recognize their target cross-presented on macrophages (Mw) leading to cytokine production. CD8 effector T cells
(CD8 TE) recognize their target on the cancer cell and get additionally activated by neighboring CD4 T cells. CD8 T cells exert direct kill on cancer
cells and high cytokine levels by CD4 and CD8 T cells lead to vessel destruction and changes in the tumor microenvironment, for example, MHC
upregulation. Apoptotic cancer cells are taken up by macrophages that cross-present tumor antigens to CD4 T cells to feed the circle.Thus, local cooperation of CD4 and CD8 T cells is
required in the effector phase to exert a bystander killing
effect [27]. In a different model, escape of antigen-
negative variants was prevented by administering poly-
clonal CD4 T cells recognizing a cross-presented alloan-
tigen [29]. Although those tumors were resistant to
checkpoint blockade, CD4 T cells restored CD8 T cell
function regarding downregulation of PD-1, proliferation,
and IFNg secretion [29]. Of note, mice were treated with
T cells, when large tumors had established.
CD4-TCRs specific for human tumor antigen
restricted to human MHC II
Most experimental models employed surrogate antigens
with the goal to translate the knowledge into the clinic by
grafting a new antigen specificity on patient’s T cells
through T cell receptor (TCR) gene transfer. In a trans-
lational model employing a therapeutically relevant anti-
gen, NY-ESO-1, TCRs were generated [30]. NY-ESO-1
is a cancer testis antigen with broad expression in differ-
ent tumor indications but limited expression in healthy
tissue [31]. Hence, it is an attractive target for TCR-T cell
therapy, if NY-ESO-1 expression is high and relatively
homogenous. Clinical studies using an affinity-enhanced
(naturally low-affine, because isolated from an antigen-
positive human cancer patient [32]) TCR recognizing an
HLA-A2-restricted epitope of NY-ESO-1 showed objec-
tive response rates of around 50% in metastatic or recur-
rent synovial sarcoma or melanoma [33,34]. Thewww.sciencedirect.com responses, however, were mainly partial and despite
persistence of TCR-transgenic T cells for at least six
months no selection for antigen-negative variants
occurred, suggesting suboptimal activity [33]. Recently,
novel TCRs were isolated from mice with a diverse
human TCR repertoire, either restricted to HLA-A2
(CD8-TCR) or HLA-DRA/DRB1*0401 (HLA-DR4)
(CD4-TCR) [30,35]. Because NY-ESO-1 is a foreign
antigen for the mice, both TCRs were of optimal affinity.
Compared to CD4-TCRs isolated from humans, the
mouse-derived human CD4-TCR were more sensitive
in peptide recognition and recognition of human mela-
noma cells, which expressed HLA-DR4. Such TCRs of
optimal affinity are likely better suited to target NY-ESO-
1-positive cancers either in a monotherapy with a CD4-
TCR or in a combined approach with CD8-TCR.
For analyzing human CD4-TCRs against human tumor
antigens in vivo, one has to take into account that the
cancer cells are usually MHC II-negative and any ther-
apeutical effect is mediated by CD4 T cells recognizing
the tumor antigen cross-presented by MHC II-positive
tumor stromal cells, likely monocytes/macrophages.
Xenograft models are, therefore, not suitable to analyze
their mode of action. To analyze the combined effect of
CD4-TCR and CD8-TCR in vivo, a model was estab-
lished, in which HLA-DR4 transgenic Rag1-deficient
mice bearing an NY-ESO-1/HLA-A2 expressing tumor,
both with a C57Bl/6 genetic background, were treatedCurrent Opinion in Immunology 2022, 74:18–24
22 Tumour immunologywith CD4-TCR and/or CD8-TCR. The TCRs were
introduced into OT-II (CD4) or P14 (CD8) T cells, which
are TCR transgenic with tumor-unrelated specificity. In
this syngeneic model, CD4 T cells recognize NY-ESO-1
cross-presented by HLA-DR4 on stromal cells, while
CD8 T cells recognize NY-ESO-1 on the cancer cells.
While CD8 T cells alone achieved tumor regression in
some mice, CD4 T cells alone only slightly impaired
tumor growth [30]. The relatively weak effect of the
CD4-TCR is likely caused by OT-II cells producing
insufficient levels of cytokines compared to wildtype
mice (unpublished observation). We hypothesize that
transgenic CD4 T cells generated from a mouse line with
physiological cytokine secretion can achieve a more sig-
nificant effect when administered as a monotherapy.
Nevertheless, only when mice were treated with both
CD4 and CD8 T cells, CD8 T cells were found in higher
numbers in the blood and in the tumor and tumors were
rejected in all mice. Macrophages isolated from the tumor
cross-presented NY-ESO-1 and stimulated TCR-trans-
duced CD4 T cells in a HLA-DR4 restricted manner
[30]. In summary, TCR-transduced CD4 and CD8 T
cells synergize in rejecting tumors.
Clinical evidence of CD4 T cell efficacy
Although clinical data on CD4 T cells in immunotherapy
are limited, several studies show the therapeutic potential
of CD4 T cells. In a case study, a patient with metastatic
melanoma experienced a durable clinical response fol-
lowing treatment with an expanded NY-ESO-1-specific
CD4 T cell clone, while subsequent patients did not show
a response [36,37]. Reasons could be that the extensive
culturing period of the T cell clone resulted in an unfa-
vorable T cell phenotype or, alternatively, due to toler-
ance mechanisms CD4 T cells with suboptimal affinity
were selected, since NY-ESO-1 is expressed in human
thymus [38]. Furthermore, treatment with ex vivo
expanded tumor-infiltrating lymphocytes (TILs)
achieved remarkable response rates, especially in mela-
noma [39]. In several cases, neoantigen-specific CD4 T
cells occurred within the TILs suggesting that they were
involved in anti-tumor immunity [40–43]. Moreover,
PD1-high or neoantigen-specific CD4 T cells in the
memory pool were identified in the peripheral blood
suggesting their previous activation [44,45]. Involve-
ment of CD4 T cells in anti-tumor immunity is further
supported by a case study, in which a cholangiocarcinoma
patient experienced regression of all lung and liver metas-
tases following transfer of TILs containing CD4 T cells
specific for mutated ERBB2IP. The patient showed
ongoing remission at six months following a second
TIL transfer, which consisted of 95% ERBB2IP-specific
CD4 T cells [46]. In a further case study, a melanoma
patient experienced a complete response after transfer of
TILs that contained a small proportion of BRAFV600E-
specific CD4 T cells, which were enriched in the periph-
ery 1–2 years following transfer [47]. Finally, in a TCRCurrent Opinion in Immunology 2022, 74:18–24 gene therapy trial, 17 patients were treated with CD4 T
cells engineered to express a MAGE-A3-reactive TCR
[48]. Three objective partial responses among nine high
dose-treated patients and one complete response among
eight low dose-treated patients were observed. However,
as clinical effects did not correlate with persistence of T
cells, more patients are needed to clearly attribute the
clinical effects to the T cell therapy.
Conclusion
CD4 T cells as effectors during regression of solid MHC
II-negative solid tumors have been underestimated.
Which of the multiple mechanisms leading to tumor
regression by CD4 T cells is prevalent, is currently
unknown. The prerequisite for CD4 T cells to recognize
tumor antigens and being activated is the uptake of the
tumor antigens by stromal cells from dying tumor cells
and presentation on MHC II molecules. Little is known
about which tumor antigens, expressed at natural levels,
are cross-presented through MHC II molecules. To bet-
ter judge the suitability of tumor antigens for CD4-TCR
gene therapy, MHC II-positive tumor stromal cells could
be isolated from human tumors or xenografts grown in
respective human MHC II-transgenic mice and tested for
recognition by CD4-TCR transduced CD4 T cells. Over-
expression of the target antigen of CD4-TCRs is certainly
an advantage, but other factors like efficiency of proces-
sing of the peptide may vary and are difficult to predict.
Neoantigens are often not overexpressed as compared to
for example cancer-testis antigens, therefore it remains to
be shown whether CD4-TCR gene therapy is more
suitable for certain classes of tumor antigens. Peptide-
MHC I binding affinity is critical for therapeutic efficacy
by CD8 T cells. The same may be true for peptide-MHC
II binding affinity for the therapeutic efficacy of CD4 T
cells. Current problems are that bioinformatic tools are
relatively poor in predicting peptide-MHC II binding
affinity and that MHC II epitopes are rarely precisely
defined for their length. An advantage of CD4-TCRs
compared to CD8-TCR may be that they less likely
select antigen-negative variants and may mediate sus-
tained regression but unlikely will they completely erad-
icate the tumor. If CD4 T cells can induce regression of
MHC II-negative tumors, as shown in experimental
models, bystander elimination of antigen-negative cancer
cells is a vital option, yet its significance for the clinic
remains to be shown.
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Tveita A: CD4+ T-cell killing of multiple myeloma cells is
mediated by resident bone marrow macrophages. Blood Adv
2020, 4:2595-2605
By using a mouse model of established multifocal myeloma, the authors
demonstrate that CD4 T cells exert anti-tumor immune responses
through interaction with tumor-resident macrophages.
12. Bogen B, Fauskanger M, Haabeth OA, Tveita A: CD4+ T cells
indirectly kill tumor cells via induction of cytotoxic
macrophages in mouse models. Cancer Immunol Immunother
2019, 68:1865-1873.
13. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B:
Secretion of tumor-specific antigen by myeloma cells is
required for cancer immunosurveillance by CD4+ T cells.
Cancer Res 2009, 69:5901-5907.
14. Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M,
Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C




Brenner E, Schörg BF, Ahmetlic F, Wieder T, Hilke FJ, Simon N,
Schroeder C, Demidov G, Riedel T, Fehrenbacher B et al.: Cancer
immune control needs senescence induction by interferon-
dependent cell cycle regulator pathways in tumours. Nat
Commun 2020, 11:1335
Adding on previous results on cytokine-induced senescence in cancer
cells, the authors show that deleting senescence-inducing cell cycle
regulators in cancer cells abrogates T cell-mediated rejection.www.sciencedirect.com 16.

Hoekstra ME, Bornes L, Dijkgraaf FE, Philips D, Pardieck IN,
Toebes M, Thommen DS, van Rheenen J, Schumacher TNM:
Long-distance modulation of bystander tumor cells by CD8+ T
cell-secreted IFNg. Nat Cancer 2020, 1:291-301
Back to back with Ref. [17], the authors show that IFNg secreted by T cells
acts over long distances in the tumor. By employing an IFNg-sensing
reporter and multiday intravital imaging they show that tumor-reactive T
cells cause IFNg-induced modulation of antigen-negative tumor cells.
17.

Thibaut R, Bost P, Milo I, Cazaux M, Lemaı̂tre F, Garcia Z, Amit I,
Breart B, Cornuot C, Schwikowski B et al.: Bystander IFN-g
activity promotes widespread and sustained cytokine
signaling altering the tumor microenvironment. Nat Cancer
2020, 1:302-314
Back to back with Ref. [16], the authors show that IFNg secreted by T cells
acts over long distances in the tumor. By analyzing STAT-1 nuclear
translocation as a proxy for IFNg signaling and intravital imaging, the
authors show the effect of IFNg on antigen-negative tumor cells.
18. Textor A, Schmidt K, Kloetzel P-M, Weißbrich B, Perez C, Charo J,
Anders K, Sidney J, Sette A, Schumacher TNM et al.: Preventing
tumor escape by targeting a post-proteasomal trimming
independent epitope. J Exp Med 2016, 213:2333-2348.
19. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W,
Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S,
Barthly L et al.: Mutations associated with acquired resistance
to PD-1 blockade in melanoma. N Engl J Med 2016, 375:819-
829.
20. Qin Z, Blankenstein T: CD4+ T cell–mediated tumor rejection
involves inhibition of angiogenesis that is dependent on IFNg
receptor expression by nonhematopoietic cells. Immunity
2000, 12:677-686.
21. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B,
Pircher H, Blankenstein T: A critical requirement of interferon
gamma-mediated angiostasis for tumor rejection by CD8+ T
cells. Cancer Res 2003, 63:4095-4100.
22. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY,
Schreiber RD, Schreiber H: CD4+ T cells eliminate MHC class II-
negative cancer cells in vivo by indirect effects of IFNg. Proc
Natl Acad Sci U S A 1999, 96:8633-8638.
23.

Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D,
Rothe M, Ivanov A, Szymborska A, Patone G, Kunz S et al.:
Tumour ischaemia by interferon-g resembles physiological
blood vessel regression. Nature 2017, 545:98-102
Using conditional IFNg receptor knock-out mice and multiday intravital
imaging the authors demonstrate that IFNg acting on tumor endothelial
cells leads to non-apoptotic blood vessel destruction and tumor
regression.
24. Listopad JJ, Kammertoens T, Anders K, Silkenstedt B,
Willimsky G, Schmidt K, Kuehl AA, Loddenkemper C,
Blankenstein T: Fas expression by tumor stroma is required for
cancer eradication. Proc Natl Acad Sci U S A 2013, 110:2276-
2281.
25. Spiotto MT, Rowley DA, Schreiber H: Bystander elimination of
antigen loss variants in established tumors. Nat Med 2004,
10:294-298.
26. Borst J, Ahrends T, Ba?bała N, Melief CJM, Kastenmüller W: CD4+




Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H:
Bystander killing of cancer requires the cooperation of CD4+
and CD8+ T cells during the effector phase. J Exp Med 2010,
207:2469-2477
In a series of tumor challenge experiments, the authors show that cancer
cells can be rejected by combined action of CD4 and CD8 T cells
targeting the stroma. The results showed that local cooperation of
CD4 and CD8 T cells is required for elimination of antigen-loss variants.
28. Bos R, Sherman LA: CD4 + T-cell help in the tumor milieu is
required for recruitment and cytolytic function of CD8 + T
lymphocytes. Cancer Res 2010, 70:8368-8377.
29.

Arina A, Karrison T, Galka E, Schreiber K, Weichselbaum RR,
Schreiber H: Transfer of allogeneic CD4 + T cells rescues CD8 +
T cells in anti-PD-L1–resistant tumors leading to tumor
eradication. Cancer Immunol Res 2017, 5:127-136Current Opinion in Immunology 2022, 74:18–24
24 Tumour immunologyHere, the authors show that relapse of regressed large tumors upon CD8
T cell therapy can be prevented by administering allogeneic CD4 T cells
either together with the CD8 T cells or at later time points.
30.

Poncette L, Chen X, Lorenz FK, Blankenstein T: Effective NY-
ESO-1-specific MHC II-restricted T cell receptors from
antigen-negative hosts enhance tumor regression. J Clin Invest
2019, 129:324-335
Employing a mouse model of T cell therapy of cancer targeting a clinically
relevant antigen, NY-ESO-1, the authors demonstrate that only the
combined action of CD8 and CD4 T cells leads to tumor regression in
all mice.
31. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S,
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